Professor Derek Hill, Chief Executive Officer of IXICO Ltd, said: “The current approaches to medical image analysis in clinical trials rely on highly-skilled radiologists and technicians ‘reading’ and painstakingly comparing images that are often acquired at different centres and different points in time. This process is expensive, time consuming and subject to error.
Our service is completely automated and uses sensitive and reproducible algorithms to quantify changes in the patient over time and hence assess the effectiveness or ineffectiveness of a treatment during trials. It can also compensate for the misplacement or movement of a patient in the scanner, compare images taken at different points in time and provide a full audit trial of the analysis process. As our service is scaleable, it can be used to analyse thousands of images in very early drug tests or in late phase trials. The end result for patients is the faster development of new, more effective treatments for painful or life threatening conditions.”
IXICO’s service has been shown to be effective in a wide variety of medical applications though the company’s initial focus is on developing its services to assess the impact of new drugs for rheumatoid arthritis, dementia and oncology. Clients include a number of major pharmaceutical and healthcare companies, for whom IXICO designs bespoke services, and the company is in advanced negotiations with additional prospective customers.
Professor Hill said: “A key feature of our technology is that the image analysis workflows in the programmes can be easily reconfigured to suit the specific requirements of different pharmaceutical companies. And we have designed our technology platform so that their staff can access the analysis results from computers in a variety of locations via a secure web portal.”
This is IXICO’s first institutional fundraising round and follows its recent success in securing a prestigious £140,000 DTI Grant for Research & Development through the London Development Agency.
Professor Hill commented on the fundraising process: “We are delighted with the success of this funding round. We spoke to several funds but were happy to work with The Capital Fund as they were prepared to share the risk with us and our angel investors by providing vital capital on straightforward terms. They have also helped us to introduce key disciplines that will be particularly useful as we grow the business.”
The Capital Fund’s Investment Manager, Helen Reynolds, said: “IXICO has created a truly innovative technology that has the potential for use across a wide range of medical applications. We were impressed by the quality of the research behind the company’s service and the calibre of the management team, especially Derek Hill, who combine substantial experience of the healthcare industry with significant image analysis acquisition know-how. We wish Derek Hill and his team every success with their future plans.”
Information integration and artificial intelligence for better diagnosis and therapy decisions
24.05.2017 | Fraunhofer MEVIS - Institut für Bildgestützte Medizin
World's thinnest hologram paves path to new 3-D world
18.05.2017 | RMIT University
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Physics and Astronomy